Form 4: Roivant President Eric Venker Executes Stock Transactions

Roivant Sciences President Eric Venker exercised options and sold 200,000 shares while settling tax obligations.

Summary

• Eric Venker, President of Roivant Sciences and CEO of Immunovant, engaged in multiple equity transactions on May 20 and May 22, 2026.
• 34,483 shares were withheld by the company for tax obligations related to RSU vesting at a price of $32.41 per share.
• 200,000 stock options were exercised at a strike price of $3.85 per share.
• 200,000 shares were subsequently sold at a weighted average price of $30.27 per share.
• Following these transactions, the reporting person maintains a direct beneficial ownership of 1,613,063 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive equity management.

Positives

• The executive maintains a significant remaining equity stake of 1,613,063 shares in the company.
• The transactions were conducted pursuant to a pre-arranged Rule 10b5-1(c) trading plan, indicating systematic rather than reactive selling.

Negatives

• The sale of 200,000 shares represents a reduction in the executive's direct holdings, though the net position remains substantial.

Risks

• Market volatility could impact the value of the remaining 1,613,063 shares held by the executive.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The transactions were executed under a Rule 10b5-1(c) plan, which is a standard mechanism for insiders to sell shares without violating insider trading regulations.

Industry Context

StockSavvy.ai notes that executive stock sales executed via 10b5-1 plans are common in the biotech sector and generally reflect planned liquidity events rather than a lack of confidence in the company's long-term pipeline.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for C-suite executives at major pharmaceutical and biotech firms to manage equity compensation.
• The net settlement of RSUs for tax purposes is a standard corporate governance practice.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were pre-planned and disclosed in accordance with SEC regulations.

Next Steps

• No future corporate actions or milestones were disclosed in this filing.

Key Dates

Keywords

Roivant Sciences, ROIV, Insider Trading, Form 4, Eric Venker, Equity Compensation